Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure
Milton Packer
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 2, pp. 371-381
Open Access | Times Cited: 22

Showing 22 citing articles:

Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Sungho Bea, Hwa Yeon Ko, Jae Hyun Bae, et al.
Gut (2024), pp. gutjnl-332687
Closed Access | Times Cited: 9
Cell type-specific regulation of the pentose phoshate pathway during development and metabolic stress-driven autoimmune diseases: Relevance for inflammatory liver, renal, endocrine, cardiovascular and neurobehavioral comorbidites, carcinogenesis, and aging
Katalin Bánki, András Perl
Autoimmunity Reviews (2025) Vol. 24, Iss. 5, pp. 103781-103781
Closed Access | Times Cited: 1
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
David Aristizábal-Colorado, Martín Ocampo Posada, Wilfredo Antonio Rivera Martínez, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 6, pp. 707-718
Closed Access | Times Cited: 5
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Kaitlin J. Mayne, Rebecca J. Sardell, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Closed Access | Times Cited: 5
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction
Wolfram Doehner, Stefan D. Anker, Javed Butler, et al.
JACC Heart Failure (2024)
Open Access | Times Cited: 5
Spatiotemporal landscape of kidney in a mouse model of hyperuricemia at single‐cell level
Haining Chang, Qianru Tao, Lan Wei, et al.
The FASEB Journal (2025) Vol. 39, Iss. 2
Open Access
D’une longue pénurie thérapeutique au triomphe des nouvelles classes d’antidiabétiques dans des maladies non métaboliques
Serge Halimi
Médecine des Maladies Métaboliques (2025)
Closed Access
Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes
Gang Greg Wang, Guixia Wang
Saudi Medical Journal (2025) Vol. 46, Iss. 3, pp. 213-225
Open Access
Uric acid promotes aortic valve calcification via mediating valve interstitial cell osteogenic differentiation and endothelial dysfunction
Jialiang Zhang, Wenhua Lei, Jing Zhou, et al.
The FASEB Journal (2025) Vol. 39, Iss. 6
Closed Access
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management
Xiao-Peng Fu
World Journal of Clinical Cases (2025) Vol. 13, Iss. 14
Closed Access
Metabolic diseases in the East Asian populations
Zhonghan Sun, Yan Zheng
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Dietary fructose: from uric acid to a metabolic switch in pediatric metabolic dysfunction-associated steatotic liver disease
Maria Felicia Faienza, Eleonora Cognetti, Ilaria Farella, et al.
Critical Reviews in Food Science and Nutrition (2024), pp. 1-16
Open Access | Times Cited: 3
Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici
Monika Bhandari, Akshyaya Pradhan, Pravesh Vishwakarma, et al.
World Journal of Cardiology (2024) Vol. 16, Iss. 10, pp. 550-563
Closed Access | Times Cited: 1
Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight
Shams Tarek Osman, Waziha Purba, Oluwatosin Daramola, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117771-117771
Open Access | Times Cited: 1
Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases
Emiliano Fiori, Ludovica De Fazio, Chiara Pidone, et al.
Journal of Hypertension (2024) Vol. 42, Iss. 10, pp. 1665-1680
Closed Access
Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
Rongfang Pan, Yuqing He, Wan Melisandre, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Pathogenetic relationship of microbiome and metabolic disorders on the background of hypertension and gout: Potential targets of pharmacotherapy
Snezhana D Sinyushkina, A. V. Gorinova, A. S. Belousova, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 16, pp. 292-301
Open Access
SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!
Brian F. Mandell
Cleveland Clinic Journal of Medicine (2024) Vol. 91, Iss. 7, pp. 392-393
Open Access
Role of HIF1A gene polymorphisms with serum uric acid and HIF-1α levels in monosodium urate crystal-induced arthritis
Javier Fernández‐Torres, Ámbar López-Macay, Yessica Zamudio‐Cuevas, et al.
Clinical Rheumatology (2024)
Closed Access
Research Progress on the Relationship between Hyperuricemia and Cardiovascular Disease
锦豪 蔡
Advances in Clinical Medicine (2024) Vol. 14, Iss. 09, pp. 308-319
Closed Access
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
Liangzhen Qu, Xueting Duan, Han Chen
ESC Heart Failure (2024)
Open Access
Contemporary prospects for the use of sodium-glucose cotransporter-2 inhibitors
Anastasia R. Kondratieva, E. A. Khazova, Alina Vadimovna Lobanova, et al.
Perm Medical Journal (2024) Vol. 41, Iss. 6, pp. 92-108
Open Access
Page 1

Scroll to top